NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability

International Journal of Cancer

Volumn 132, Issue 6, 2013, Pages 1360-1367

  Sommermeyer, Daniel ^a   Conrad, Heinke ^b,c   Krönig, Holger ^c   Gelfort, Haike ^a   Bernhard, Helga ^b,c,d   Uckert, Wolfgang ^a,e  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d KLINIKUM DARMSTADT   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

cytotoxic T cells; human; NY ESO 1; T cell receptor; tumor immunity

Indexed keywords

HLA A2 ANTIGEN; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CELL CLONE; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; EPITOPE MAPPING; GENE CONSTRUCT; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; HLA-A2 ANTIGEN; HUMANS; IMMUNOTHERAPY; MEMBRANE PROTEINS; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84872970555     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27792     Document Type: Article

References (28)

1. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30. (Pubitemid 44088423)
2. Chen YT, Scanlan MJ, Sahin U, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 1914-18. (Pubitemid 27113936)
3. Jager E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 265-70. (Pubitemid 28060443)
4. Jager E, Jager D, Karbach J, et al. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB40101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191: 625-30.
5. Bender A, Karbach J, Neumann A, et al. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun 2007; 7: 16.
6. Gotter J, Brors B, Hergenhahn M, et al. Medullary epithelial cells of the human thymus express a highly diverse selection of tissue-specific genes colocalized in chromosomal clusters. J Exp Med 2004; 199: 155-66. (Pubitemid 38139246)
7. Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-24.
8. Wilde S, Sommermeyer D, Frankenberger B, et al. Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity. Blood 2009; 114: 2131-9.
9. Stauss HJ,. Immunotherapy with CTLs restricted by nonself MHC. Immunol Today 1999; 20: 180-3.
10. Falkenburg WJ, Melenhorst JJ, van de Meent M, et al. Allogeneic HLA-A02-restricted WT1-specific t cells from mismatched donors are highly reactive but show off-target promiscuity. J Immunol 2011; 187: 2824-33.
11. Zhao Y, Zheng Z, Robbins PF, et al. Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J Immunol 2005; 174: 4415-23. (Pubitemid 40396025)
12. Schmid DA, Irving MB, Posevitz V, et al. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 2010; 184: 4936-46.
13. Carey TE, Takahashi T, Resnick LA, et al. Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci USA 1976; 73: 3278-82.
14. Rimoldi D, Rubio-Godoy V, Dutoit V, et al. Efficient simultaneous presentation of NY-ESO-1/LAGE-1 primary and nonprimary open reading frame-derived CTL epitopes in melanoma. J Immunol 2000; 165: 7253-61. (Pubitemid 32001204)
15. Fleischer K, Schmidt B, Kastenmuller W, et al. Melanoma-reactive class I-restricted cytotoxic T cell clones are stimulated by dendritic cells loaded with synthetic peptides, but fail to respond to dendritic cells pulsed with melanoma-derived heat shock proteins in vitro. J Immunol 2004; 172: 162-9. (Pubitemid 38020468)
16. Leisegang M, Wilde S, Spranger S, et al. MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest 2010; 120: 3869-77.
17. Kronig H, Hofer K, Conrad H, et al. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity. Int J Cancer 2009; 125: 649-55.
18. Neudorfer J, Schmidt B, Huster KM, et al. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007; 320: 119-31. (Pubitemid 46349106)
19. Meyer zum Buschenfelde C, Nicklisch N, Rose-John S, et al. Generation of tumor-reactive CTL against the tumor-Associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J Immunol 2000; 165: 4133-40. (Pubitemid 32057326)
20. Sommermeyer D, Uckert W,. Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells. J Immunol 2010; 184: 6223-31.
21. Kuball J, Dossett ML, Wolfl M, et al. Facilitating matched pairing and expression of TCR chains introduced into human T cells. Blood 2007; 109: 2331-8. (Pubitemid 46425872)
22. Cohen CJ, Li YF, El-Gamil M, et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res 2007; 67: 3898-903. (Pubitemid 46762178)
23. Leisegang M, Engels B, Meyerhuber P, et al. Enhanced functionality of T cell receptor-redirected T cells is defined by the transgene cassette. J Mol Med 2008; 86: 573-83.
24. Scholten KB, Kramer D, Kueter EW, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol 2006; 119: 135-45.
25. Engels B, Cam H, Schuler T, et al. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther 2003; 14: 1155-68. (Pubitemid 36930405)
26. Van Parijs L, Refaeli Y, Lord JD, et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 1999; 11: 281-8. (Pubitemid 29463236)
27. Sommermeyer D, Neudorfer J, Weinhold M, et al. Designer T cells by T cell receptor replacement. Eur J Immunol 2006; 36: 3052-9. (Pubitemid 44782577)
28. Lyons GE, Roszkowski JJ, Man S, et al. T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother 2006; 55: 1142-50. (Pubitemid 43800729)